Skip to main content
Advertisement

Main menu

  • Home
  • Content
    • Current Issue
    • Accepted Manuscripts
    • Article Preview
    • Past Issue Archive
    • Video Articles
    • AJNR Case Collection
    • Case of the Week Archive
    • Case of the Month Archive
    • Classic Case Archive
  • Special Collections
    • AJNR Awards
    • Low-Field MRI
    • Alzheimer Disease
    • ASNR Foundation Special Collection
    • Photon-Counting CT
    • View All
  • Multimedia
    • AJNR Podcasts
    • AJNR SCANtastic
    • Trainee Corner
    • MRI Safety Corner
    • Imaging Protocols
  • For Authors
    • Submit a Manuscript
    • Submit a Video Article
    • Submit an eLetter to the Editor/Response
    • Manuscript Submission Guidelines
    • Statistical Tips
    • Fast Publishing of Accepted Manuscripts
    • Graphical Abstract Preparation
    • Imaging Protocol Submission
    • Author Policies
  • About Us
    • About AJNR
    • Editorial Board
    • Editorial Board Alumni
  • More
    • Become a Reviewer/Academy of Reviewers
    • Subscribers
    • Permissions
    • Alerts
    • Feedback
    • Advertisers
    • ASNR Home

User menu

  • Alerts
  • Log in

Search

  • Advanced search
American Journal of Neuroradiology
American Journal of Neuroradiology

American Journal of Neuroradiology

ASHNR American Society of Functional Neuroradiology ASHNR American Society of Pediatric Neuroradiology ASSR
  • Alerts
  • Log in

Advanced Search

  • Home
  • Content
    • Current Issue
    • Accepted Manuscripts
    • Article Preview
    • Past Issue Archive
    • Video Articles
    • AJNR Case Collection
    • Case of the Week Archive
    • Case of the Month Archive
    • Classic Case Archive
  • Special Collections
    • AJNR Awards
    • Low-Field MRI
    • Alzheimer Disease
    • ASNR Foundation Special Collection
    • Photon-Counting CT
    • View All
  • Multimedia
    • AJNR Podcasts
    • AJNR SCANtastic
    • Trainee Corner
    • MRI Safety Corner
    • Imaging Protocols
  • For Authors
    • Submit a Manuscript
    • Submit a Video Article
    • Submit an eLetter to the Editor/Response
    • Manuscript Submission Guidelines
    • Statistical Tips
    • Fast Publishing of Accepted Manuscripts
    • Graphical Abstract Preparation
    • Imaging Protocol Submission
    • Author Policies
  • About Us
    • About AJNR
    • Editorial Board
    • Editorial Board Alumni
  • More
    • Become a Reviewer/Academy of Reviewers
    • Subscribers
    • Permissions
    • Alerts
    • Feedback
    • Advertisers
    • ASNR Home
  • Follow AJNR on Twitter
  • Visit AJNR on Facebook
  • Follow AJNR on Instagram
  • Join AJNR on LinkedIn
  • RSS Feeds

AJNR Awards, New Junior Editors, and more. Read the latest AJNR updates

Review ArticleReview Articles
Open Access

The Role of Functional Dopamine-Transporter SPECT Imaging in Parkinsonian Syndromes, Part 1

T.C. Booth, M. Nathan, A.D. Waldman, A.-M. Quigley, A.H. Schapira and J. Buscombe
American Journal of Neuroradiology February 2015, 36 (2) 229-235; DOI: https://doi.org/10.3174/ajnr.A3970
T.C. Booth
aFrom the Department of Neuroradiology (T.C.B.), National Hospital for Neurology and Neurosurgery, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Nathan
bDepartment of Nuclear Medicine (M.N., A.-M.Q.), Royal Free Hospital National Health Service Trust, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A.D. Waldman
cDepartment of Imaging (A.D.W.), Imperial College Healthcare National Health Service Trust, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A.-M. Quigley
bDepartment of Nuclear Medicine (M.N., A.-M.Q.), Royal Free Hospital National Health Service Trust, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A.H. Schapira
dDepartment of Clinical Neurosciences (A.H.S.), Institute of Neurology, University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Buscombe
eDepartment of Nuclear Medicine (J.B.), Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • Responses
  • References
  • PDF
Loading

REFERENCES

  1. 1.↵
    1. Scherfler C,
    2. Schwarz J,
    3. Antonini A, et al
    . Role of DAT-SPECT in the diagnostic work-up of parkinsonism. Mov Disord 2007;22:1229–38
    CrossRefPubMed
  2. 2.↵
    1. Catafau AM,
    2. Tolosa E
    . Impact of dopamine transporter SPECT using 123I-ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes. Mov Disord 2004;19:1175–82
    CrossRefPubMedWeb of Science
  3. 3.↵
    1. Hughes AJ,
    2. Daniel SE,
    3. Kilford L, et al
    . Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–84
    Abstract/FREE Full Text
  4. 4.↵
    1. Booij J,
    2. Tissingh G,
    3. Winogrodzka A, et al
    . Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med 1999;26:171–82
    CrossRefPubMedWeb of Science
  5. 5.↵
    1. Seppi K
    . MRI for the differential diagnosis of neurodegenerative parkinsonism in clinical practice. Parkinsonism Relat Disord 2007;13:S400–05
    CrossRefPubMed
  6. 6.↵
    1. Sitburana O,
    2. Ondo WG
    . Brain magnetic resonance imaging (MRI) in parkinsonian disorders. Parkinsonism Rel Disord 2009;15:165–74
    CrossRef
  7. 7.↵
    1. Kaufman MJ,
    2. Madras BK
    . Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's diseased striatum. Synapse 1991;9:43–49
    CrossRefPubMedWeb of Science
  8. 8.↵
    1. Melikian HG,
    2. Buckley KM
    . Membrane trafficking regulates the activity of the human dopamine transporter. J Neurosci 1999;19:7699–710
    Abstract/FREE Full Text
  9. 9.↵
    1. Garcia BG,
    2. Wei Y,
    3. Moron JA, et al
    . Akt is essential for insulin modulation of amphetamine-induced human dopamine transporter cell-surface redistribution. Mol Pharmacol 2005;68:102–09
    Abstract/FREE Full Text
  10. 10.↵
    1. Fahn S,
    2. Oakes D,
    3. Shoulson I, et al
    . Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498–508
    CrossRefPubMedWeb of Science
  11. 11.↵
    1. Neumeyer JL,
    2. Wang S,
    3. Gao Y, et al
    . N-omega-fluoroalkyl analogues of (1R)-2 beta-carbomethoxy-3 beta-(4-iodophenyl)-tropane (beta-CIT): radiotracers for positron emission tomography and single photon emission computed tomography imaging of dopamine transporters. J Med Chem 1994;37:1558–61
    CrossRefPubMed
  12. 12.↵
    1. Booij J,
    2. Andringa G,
    3. Rijks LJ, et al
    . 123I-FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP-lesioned monkeys. Synapse 1997;27:183–90
    CrossRefPubMedWeb of Science
  13. 13.↵
    1. Mozley PD,
    2. Schneider JS,
    3. Acton PD, et al
    . Binding of [99mTc-]TRODAT-1 to dopamine transporters in patients with Parkinson's disease and in healthy volunteers. J Nucl Med 2000;41:584–89
    Abstract/FREE Full Text
  14. 14.↵
    1. Kim HJ,
    2. Im JH,
    3. Yang SO, et al
    . Imaging and quantification of dopamine transporters with iodine-123-IPT in normal and Parkinson's disease subjects. J Nucl Med 1997;38:1703–11
    Abstract/FREE Full Text
  15. 15.↵
    1. Booij J,
    2. Hemelaar TG,
    3. Speelman JD, et al
    . One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I]FPCIT SPECT. J Nucl Med 1999;40:753–61
    Abstract/FREE Full Text
  16. 16.↵
    1. Hughes AJ,
    2. Daniel SE,
    3. Ben-Shlomo Y, et al
    . The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002;125:861–70
    Abstract/FREE Full Text
  17. 17.↵
    1. Marshall VL,
    2. Reininger CB,
    3. Marquardt M, et al
    . Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov Disord 2009;24:500–08
    CrossRefPubMedWeb of Science
  18. 18.↵
    1. Kupsch AR,
    2. Bajaj N,
    3. Weiland F, et al
    . Impact of DaTscan SPECT imaging on clinical management, diagnosis, confidence of diagnosis, quality of life, health resource use and safety in patients with clinically uncertain parkinsonian syndromes: a prospective 1-year follow-up of an open-label controlled study. J Neurol Neurosurg Psychiatry 2012;83:620–28
    Abstract/FREE Full Text
  19. 19.↵
    1. Acton PD,
    2. Newberg A,
    3. Ploessl K, et al
    . Comparison of region-of-interest analysis and human observers in the diagnosis of Parkinson's disease using [99mTc]Trodat-1 and SPECT. Phys Med Biol 2006;51:575–85
    CrossRefPubMed
  20. 20.↵
    1. Djang DS,
    2. Janssen MJ,
    3. Bohnen N, et al
    . SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT 1.0. J Nucl Med 2012;53:154–63
    FREE Full Text
  21. 21.↵
    1. Yekhlef F,
    2. Ballan G,
    3. Macia F, et al
    . Routine MRI for the differential diagnosis of Parkinson's disease, MSA, PSP, and CBD. J Neural Transm 2003;110:151–69
    CrossRefPubMedWeb of Science
  22. 22.↵
    1. Savoiardo M
    . Differential diagnosis of Parkinson's disease and atypical parkinsonian disorders by magnetic resonance imaging. Neurol Sci 2003;24(Suppl 1):S35–37
    CrossRefPubMed
  23. 23.↵
    1. Aquino D,
    2. Contarino V,
    3. Albanese A, et al
    . Substantia nigra in Parkinson's disease: a multimodal MRI comparison between early and advanced stages of the disease. Neurol Sci 2014;35:753–58
    CrossRefPubMed
  24. 24.↵
    1. Nagano-Saito A,
    2. Washimi Y,
    3. Arahata Y, et al
    . Cerebral atrophy and its relation to cognitive impairment in Parkinson disease. Neurology 2005;64:224–29
    CrossRef
  25. 25.↵
    1. Scherfler C,
    2. Schocke MF,
    3. Seppi K, et al
    . Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson's disease. Brain 2006;129:538–42
    Abstract/FREE Full Text
  26. 26.↵
    1. Clarke CE,
    2. Lowry M
    . Systematic review of proton magnetic resonance spectroscopy of the striatum in parkinsonian syndromes. Eur J Neurol 2001;8:573–77
    CrossRefPubMedWeb of Science
  27. 27.↵
    1. Gaenslen A,
    2. Unmuth B,
    3. Godau J, et al
    . The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study. Lancet Neurol 2008;7:417–24
    CrossRefPubMedWeb of Science
  28. 28.↵
    1. Berg D,
    2. Godau J,
    3. Walter U
    . Transcranial sonography in movement disorders. Lancet Neurol 2008;7:1044–55
    CrossRefPubMedWeb of Science
  29. 29.↵
    1. Morrish PK,
    2. Rakshi JS,
    3. Bailey DL, et al
    . Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 1998;64:314–19
    Abstract/FREE Full Text
  30. 30.↵
    1. Brooks DJ,
    2. Salmon EP,
    3. Mathias CJ, et al
    . The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET. Brain 1990;113:1539–52
    Abstract/FREE Full Text
  31. 31.↵
    1. Khan NL,
    2. Valente EM,
    3. Bentivoglio AR, et al
    . Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. Ann Neurol 2002;52:849–53
    CrossRefPubMedWeb of Science
  32. 32.↵
    1. Ghaemi M,
    2. Hilker R,
    3. Rudolf J, et al
    . Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET. J Neurol Neurosurg Psychiatry 2002;73:517–23
    Abstract/FREE Full Text
  33. 33.↵
    1. Antonini A,
    2. Leenders KL,
    3. Vontobel P, et al
    . Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain 1997;120:2187–95
    Abstract/FREE Full Text
  34. 34.↵
    1. Innis RB,
    2. Seibyl JP,
    3. Scanley BE, et al
    . Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci U S A 1993;90:11965–69
    Abstract/FREE Full Text
  35. 35.↵
    1. Brücke T,
    2. Asenbaum S,
    3. Pirker W, et al
    . Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT: correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl 1997;50:9–24
    CrossRefPubMed
  36. 36.↵
    1. Varrone A,
    2. Pellecchia MT,
    3. Amboni M, et al
    . Imaging of dopaminergic dysfunction with [123I]FP-CIT SPECT in early-onset parkin disease. Neurology 2004;63:2097–103
    CrossRef
  37. 37.↵
    1. Benamer TS,
    2. Patterson J,
    3. Grosset DG, et al
    . Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 2000;15:503–10
    CrossRefPubMedWeb of Science
  38. 38.↵
    1. Vlaar AM,
    2. van Kroonenburgh MJ,
    3. Kessels AG, et al
    . Meta-analysis of the literature on the diagnostic accuracy of SPECT in parkinsonian syndromes. BMC Neurol 2007;7:27
    CrossRefPubMed
  39. 39.↵
    Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653–61
    CrossRefPubMedWeb of Science
  40. 40.↵
    1. Bernheimer H,
    2. Birkmayer W,
    3. Hornykiewicz O, et al
    . Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological and neurochemical correlations. J Neurol Sci 1973;20:415–55
    CrossRefPubMedWeb of Science
  41. 41.↵
    1. Bezard E,
    2. Dovero S,
    3. Prunier C, et al
    . Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4phenyl-1,2,3,5-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci 2001;21:6853–61
    Abstract/FREE Full Text
  42. 42.↵
    1. Tissingh G,
    2. Bergmans P,
    3. Booij J, et al
    . Drug-naive patients with Parkinson's disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [123I]beta-CIT SPECT. J Neurol 1998;245:14–20
    CrossRefPubMedWeb of Science
  43. 43.↵
    1. Ponsen MM,
    2. Stoffers D,
    3. Wolters EC, et al
    . Olfactory testing combined with dopamine transporter imaging as a method to detect prodromal Parkinson's disease. J Neurol Neurosurg Psychiatry 2010;81:396–99
    Abstract/FREE Full Text
  44. 44.↵
    1. van Dyck CH,
    2. Seibyl JP,
    3. Malison RT, et al
    . Age-related decline in striatal dopamine transporter binding with iodine-123-beta-CIT SPECT. J Nucl Med 1995;36:1175–81
    Abstract/FREE Full Text
  45. 45.↵
    1. Ravina B,
    2. Eidelberg D,
    3. Ahlskog JE, et al
    . The role of radiotracer imaging in Parkinson's disease. Neurology 2005;64:208–15
    CrossRef
PreviousNext
Back to top

In this issue

American Journal of Neuroradiology: 36 (2)
American Journal of Neuroradiology
Vol. 36, Issue 2
1 Feb 2015
  • Table of Contents
  • Index by author
  • Complete Issue (PDF)
Advertisement
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on American Journal of Neuroradiology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Role of Functional Dopamine-Transporter SPECT Imaging in Parkinsonian Syndromes, Part 1
(Your Name) has sent you a message from American Journal of Neuroradiology
(Your Name) thought you would like to see the American Journal of Neuroradiology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Cite this article
T.C. Booth, M. Nathan, A.D. Waldman, A.-M. Quigley, A.H. Schapira, J. Buscombe
The Role of Functional Dopamine-Transporter SPECT Imaging in Parkinsonian Syndromes, Part 1
American Journal of Neuroradiology Feb 2015, 36 (2) 229-235; DOI: 10.3174/ajnr.A3970

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
0 Responses
Respond to this article
Share
Bookmark this article
The Role of Functional Dopamine-Transporter SPECT Imaging in Parkinsonian Syndromes, Part 1
T.C. Booth, M. Nathan, A.D. Waldman, A.-M. Quigley, A.H. Schapira, J. Buscombe
American Journal of Neuroradiology Feb 2015, 36 (2) 229-235; DOI: 10.3174/ajnr.A3970
del.icio.us logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Purchase

Jump to section

  • Article
    • Abstract
    • ABBREVIATIONS:
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • Responses
  • References
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Pitfalls and Artifacts of 123I-Ioflupane SPECT in Parkinsonian Syndromes: A Quality Improvement Teaching Tool
  • Crossref (57)
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • An Explainable Machine Learning Model for Early Detection of Parkinson's Disease using LIME on DaTSCAN Imagery
    Pavan Rajkumar Magesh, Richard Delwin Myloth, Rijo Jackson Tom
    Computers in Biology and Medicine 2020 126
  • Dopamine and Dopamine Receptors in Alzheimer's Disease: A Systematic Review and Network Meta-Analysis
    Xiongfeng Pan, Atipatsa C. Kaminga, Shi Wu Wen, Xinyin Wu, Kwabena Acheampong, Aizhong Liu
    Frontiers in Aging Neuroscience 2019 11
  • Importance of low diagnostic Accuracy for early Parkinson's disease
    Thomas G. Beach, Charles H. Adler
    Movement Disorders 2018 33 10
  • Targeting mitophagy in Parkinson's disease
    Emily H. Clark, Aurelio Vázquez de la Torre, Tamaki Hoshikawa, Thomas Briston
    Journal of Biological Chemistry 2021 296
  • Linking Essential Tremor to the Cerebellum—Neuroimaging Evidence
    Antonio Cerasa, Aldo Quattrone
    The Cerebellum 2016 15 3
  • From simultaneous to synergistic MR‐PET brain imaging: A review of hybrid MR‐PET imaging methodologies
    Zhaolin Chen, Sharna D. Jamadar, Shenpeng Li, Francesco Sforazzini, Jakub Baran, Nicholas Ferris, Nadim Jon Shah, Gary F. Egan
    Human Brain Mapping 2018 39 12
  • Augmented Intelligence in Healthcare: A Pragmatic and Integrated Analysis
    Aryan Mohanty, Sushruta Mishra
    2022 1024
  • Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling Analysis
    Daniela J. Conrado, Timothy Nicholas, Kuenhi Tsai, Sreeraj Macha, Vikram Sinha, Julie Stone, Brian Corrigan, Massimo Bani, Pierandrea Muglia, Ian A. Watson, Volker D. Kern, Elena Sheveleva, Kenneth Marek, Diane T. Stephenson, Klaus Romero
    Clinical and Translational Science 2018 11 1
  • Neuromelanin MRI is useful for monitoring motor complications in Parkinson’s and PARK2 disease
    Taku Hatano, Ayami Okuzumi, Koji Kamagata, Kensuke Daida, Daisuke Taniguchi, Masaaki Hori, Hiroyo Yoshino, Shigeki Aoki, Nobutaka Hattori
    Journal of Neural Transmission 2017 124 4
  • Imaging analysis of Parkinson’s disease patients using SPECT and tractography
    Seong-Jin Son, Mansu Kim, Hyunjin Park
    Scientific Reports 2016 6 1

More in this TOC Section

  • An Atlas of Neonatal Neurovascular Imaging Anatomy as Depicted with Microvascular Imaging: The Intracranial Arteries
  • An Atlas of Neonatal Neurovascular Imaging Anatomy as Depicted with Microvascular Imaging: The Intracranial Veins
  • Clinical Translation of Hyperpolarized 13C Metabolic Probes for Glioma Imaging
Show more Review articles

Similar Articles

Advertisement

Indexed Content

  • Current Issue
  • Accepted Manuscripts
  • Article Preview
  • Past Issues
  • Editorials
  • Editor's Choice
  • Fellows' Journal Club
  • Letters to the Editor
  • Video Articles

Cases

  • Case Collection
  • Archive - Case of the Week
  • Archive - Case of the Month
  • Archive - Classic Case

More from AJNR

  • Trainee Corner
  • Imaging Protocols
  • MRI Safety Corner
  • Book Reviews

Multimedia

  • AJNR Podcasts
  • AJNR Scantastics

Resources

  • Turnaround Time
  • Submit a Manuscript
  • Submit a Video Article
  • Submit an eLetter to the Editor/Response
  • Manuscript Submission Guidelines
  • Statistical Tips
  • Fast Publishing of Accepted Manuscripts
  • Graphical Abstract Preparation
  • Imaging Protocol Submission
  • Evidence-Based Medicine Level Guide
  • Publishing Checklists
  • Author Policies
  • Become a Reviewer/Academy of Reviewers
  • News and Updates

About Us

  • About AJNR
  • Editorial Board
  • Editorial Board Alumni
  • Alerts
  • Permissions
  • Not an AJNR Subscriber? Join Now
  • Advertise with Us
  • Librarian Resources
  • Feedback
  • Terms and Conditions
  • AJNR Editorial Board Alumni

American Society of Neuroradiology

  • Not an ASNR Member? Join Now

© 2025 by the American Society of Neuroradiology All rights, including for text and data mining, AI training, and similar technologies, are reserved.
Print ISSN: 0195-6108 Online ISSN: 1936-959X

Powered by HighWire